<DOC>
	<DOCNO>NCT01813370</DOCNO>
	<brief_summary>The purpose study continue follow-up patient treat study call TAX 3505 ( MSK IRB # 07-101 ) . The sponsor study , decide end study early , patient complete planned follow-up test . As result , investigator yet know whether hormonal therapy alone , combination docetaxel , good prevent prostate cancer recurrence patient rise PSA prostatectomy . This study continue follow patient accord schedule similar find TAX 3503 ( MSK IRB # 07-101 ) study order answer question . This study know registry study . The patient ' receive treatment part study . Instead , ask blood test perform every 12 week .</brief_summary>
	<brief_title>A Registry Patients Treated Clinical Trial TAX 3503</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>The registry include database patient register TAX3503 . Those patient prospectively track registry meet follow criterion : 1 . The patient must register TAX3503 2 . The patient must meet definition progression define TAX3503 TAX3503 Patients progress hit 36 month post treatment date closure TAX3503 activation TAX3503 Registry protocol permit study capture date progression 36 month post treatment progression free date . Patients register TAX3503 eligible data store registry .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>TAX 3503</keyword>
	<keyword>MSKCC IRB # 07-101</keyword>
	<keyword>12-225</keyword>
</DOC>